What is claimed is

1. An ophthalmic device comprising about a minimum effective amount of an anti-allergic agent wherein the ophthalmic device is etafilcon A and the anti-allergic agent is ketotifen or pharmaceutically acceptable salts and mixtures thereof.

2. An ophthalmic device comprising about a minimum effective amount of an anti-allergic agent wherein the ophthalmic device is etafilcon A, the anti-allergic agent is ketotifen or pharmaceutically acceptable salts and mixtures thereof, and the minimum effective amount of the antiallergic agent is about 8 μg to about 90 μg.

3. An ophthalmic device comprising about a minimum effective amount of an anti-allergic agent wherein the ophthalmic device is etafilcon A, the anti-allergic agent is ketotifen or pharmaceutically acceptable salts and mixtures thereof, and the minimum effective amount of the antiallergic agent is about 10 μg to about 40 μg.

4. An ophthalmic device comprising about a minimum effective amount of an anti-allergic agent wherein the ophthalmic device is etafilcon A, the anti-allergic agent is ketotifen or pharmaceutically acceptable salts and mixtures thereof, and the minimum effective amount of the antiallergic agent is about 10 μg to about 25 μg.

5. A method of making an ophthalmic device comprising about a minimum effective amount of an anti-allergic agent comprising the step of treating an ophthalmic device with a solution comprising said anti-allergic agent, wherein the amount of said anti-allergic agent in said solution exceeds the minimum effective amount.

6. The method of claim 5 wherein the minimum effective amount is exceeded by about 20% and about 1000%, in a volume of solution that is between about 500 μL and about 5000 μL.

7. The method of claim 5 wherein the minimum effective amount is exceeded by between about 50% and about 500%, in a volume of solution that is between about 500 μL and about 3000 μL.

8. The method of claim 5 wherein the minimum effective amount is exceeded by about 50% in a volume of solution that is about 1000 μL.

CLAIMS:

1. An ophthalmic device for alleviating symptoms of allergic conjunctivitis in a patient comprising a minimum effective amount of an anti-allergic agent, wherein, the ophthalmic device is prepared from a formulation comprising etafilcon A, the anti-allergic agent is selected from the group consisting of ketotifen, its pharmaceutically acceptable salts and mixtures thereof, the minimum effective amount of said anti-allergic agent is 8 µg to 90 µg, and said ophthalmic device releases between about 10% and about 90% of its contained anti-allergic agent between administering the device to the eye and about 60 minutes.

2. The ophthalmic device of claim 1 wherein the minimum effective amount of the anti-allergic agent is about 10 µg to about 40 µg.

3. The ophthalmic device of claim 1 wherein the minimum effective amount of the anti-allergic agent is about 10 µg to about 25 µg.

4. A method of making an ophthalmic device comprising about a minimum effective amount of an anti-allergic agent comprising the step of treating an ophthalmic device with a solution comprising said anti-allergic agent, wherein the amount of said anti-allergic agent in said solution exceeds the minimum effective amount; wherein, the ophthalmic device is prepared from a formulation comprising etafilcon A, the anti-allergic agent is selected from the group consisting of ketotifen, its pharmaceutically acceptable salts and mixtures thereof, the minimum effective amount of said anti-allergic agent is 8 µg to 90 µg, and said ophthalmic device releases between about 10% and about 90% of its contained anti-allergic agent between administering the device to the eye and about 60 minutes, wherein the minimum effective amount is exceeded by between about 20% and about 1000%, in a volume of solution that is between about 500 µL and about 5000 µL.

5. The method of claim 4 wherein the minimum effective amount is exceeded by between about 50% and about 500%, in a volume of solution that is between about 500 µL and about 3000 µL.

6. The method of claim 4 wherein the minimum effective amount is exceeded by about 50% in a volume of solution that is about 1000 µL.

7. A method of preventing oxidation of an ophthalmic device comprising an anti-allergic agent, wherein the method includes treating said ophthalmic device with a solution comprising an oxidative stabilization agent; wherein, the ophthalmic device is prepared from a formulation comprising etafilcon A, the anti-allergic agent is selected from the group consisting of ketotifen, its pharmaceutically acceptable salts and mixtures thereof, the minimum effective amount of said anti-allergic agent is 8 µg to 90 µg, and said ophthalmic device releases between about 10% and about 90% of its contained anti-allergic agent between administering the device to the eye and about 60 minutes.

8. The method of claim 7 wherein the oxidative stabilization agent is selected from the group consisting of DTPA, EDTA, Dequest, Desferal, silica, chitosan, cellulose, N,N,N',N',N", N"-hexa(2-pyridyl)-1,3,5-tris(aminomethyl)benzene, crown ethers, ligand containing knots, catenands, and mixtures thereof.

9. The method of claim 7 wherein the oxidative stabilization agent is selected from the group consisting of 2,2',2",6,6',6"-Hexa-(1,1-dimethylethyl)4,4',4"-[(2,4,6-trimethyl-1,3,5-benzenetriyl)-trismethylene]-triphenol (Irganox 1330), 1,3,5tris[3,5-di(1,1-dimethylethyl)4-hydroxybenzyl]-1H,3H,5H-1,3,5-triazine-2,4,6-trione, pentaerythrityl tetrakis[3-[3,5-di(1,1-dimethylethyl)-4-hydroxyphenyl]-propionate], octadecyl-3-[3,5-di(1,1-dimethylethyl)-4-hydroxyphenyl]-propionate, tris[2,4-di(1,1-dimethylethyl)-phenyl]-phosphite, 2,2'-di(octadecyloxy)-5,5'-spirobi(1,3,2-dioxaphosphorinane), dioctadecyl disulphide, didodecyl-3,3'-thiodipropionate,

dioctadecyl-3,3'-thiodipropionate, butylhydroxytoluene, ethylene bis[3,3-di[3-(1,1-dimethylethyl)-4-hydroxyphenyl]butyrate] and mixtures thereof.

10. The method of claim 7 wherein the oxidative stabilization agent is selected from the group consisting of DTPA, $CaNa_3DTPA$, $ZnNa_3DTPA$, and Ca_2DTPA.

11. The ophthalmic device of claim 1 comprising a localized amount of the anti-allergic agent.

12. The device of claim 11 wherein the localized amount is about 2 µg to about 20 µg and said localized amount is in contact with the conjunctiva.